This antibody targets a transcription activator that regulates abscisic acid (ABA) biosynthesis and signaling. It achieves this by binding to the specific promoter motif 5'- (A/T)AACCAT-3'. Furthermore, it represses ABA-mediated salt stress tolerance (e.g., NaCl and KCl) and influences leaf morphology, promoting vegetative growth.
To confirm SRM1 antibody specificity:
Perform knockout (KO) validation using tissues/cells from SARM1 KO models (e.g., prion-infected mice showing no SARM1 expression in mitochondrial assays) .
Combine Western blotting and immunohistochemistry (IHC) to verify band size (predicted: ~70 kDa) and subcellular localization (mitochondrial/nuclear) .
Use pre-adsorption controls with recombinant SRM1 protein to block antigen binding .
Follow a tiered approach:
Start with manufacturer-recommended dilutions (e.g., 1:100–1:500 for IHC).
Test serial dilutions in positive control tissues (e.g., brain thalamus for mitochondrial localization) .
Validate using secondary antibody-only controls to eliminate background noise .
| Parameter | Direct Method | Indirect Method |
|---|---|---|
| Sensitivity | Low | High |
| Cross-reactivity | Minimal | Requires validation |
| Time | 1–2 hours | 4–6 hours |
| Signal Amplification | None | Yes (via secondary) |
| Adapted from |
Conflicting reports (e.g., increased mitochondrial respiration in SARM1 KO mice vs. reduced activity in yeast models) require:
Model-specific validation: Compare antibody performance across species (e.g., murine vs. yeast SRM1 homologs) using cross-reactivity alignment tools (>85% sequence homology recommended) .
Functional assays: Pair antibody-based detection with mitochondrial respirometry (e.g., Seahorse assays) to correlate protein levels with oxidative activity .
SRM1 nuclear accumulation increases with cellular aging . Address this by:
Synchronizing cell cycles in cultured models to control for mitotic stage.
Including age-matched controls in animal studies (e.g., 75 DPI timepoints for prion models) .
Using dual staining with cell cycle markers (e.g., Ki67) to contextualize localization patterns .
Cross-link free vs. cross-linked protocols: Test both to distinguish direct interactions (e.g., SRM1-GSP1 binding) from indirect associations .
CRISPR-edited lines: Use SRM1 KO cells to confirm loss of co-precipitated targets (e.g., mitochondrial complexes II/IV) .
Mass spectrometry validation: Compare IP eluates from wild-type and KO models to identify non-specific binders .
Request lot-specific validation data from suppliers, focusing on EC50 values in ELISA or neutralization titers .
Establish an internal reference standard (e.g., a validated lysate) for normalization across experiments .
Antigen retrieval: Optimize pH (6.0–9.0) and heating time (20–40 mins) based on fixation method .
Post-translational modifications: Treat samples with phosphatases/proteases if studying phosphorylation-dependent epitopes .
Multiplex staining: Combine with mitochondrial markers (e.g., COX IV) to confirm subcellular patterns .